Medicenna Gains CA$20M Boost for Cancer Immunotherapy
Company Announcements

Medicenna Gains CA$20M Boost for Cancer Immunotherapy

Medicenna Therapeutics (TSE:MDNA) has released an update.

Medicenna Therapeutics has secured a CA$20 million investment from RA Capital Management to support the advancement of its lead program MDNA11 and other preclinical superkine immunotherapies. The non-brokered private placement will strengthen the company’s financial position and extend its cash runway into 2026. This strategic funding highlights RA Capital Management’s confidence in Medicenna’s innovative approach to cancer treatment through engineered cytokines.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedicenna to Present Innovative Cancer Data at Conferences
TipRanks Canadian Auto-Generated NewsdeskMedicenna Reports Promising Results with MDNA11
TipRanks Canadian Auto-Generated NewsdeskMedicenna Announces Breakthroughs in Cancer Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App